biguanides suppress hepatic glucagon signalling decreasing production cyclic amp 
glucose production liver essential providing substrate brain fasting inability insulin suppress hepatic glucose output major aetiological factor hyperglycaemia type diabetes mellitus diseases insulin resistance fifty years one classes therapeutics effective reducing glucose production biguanides include phenformim metformin latter frequently prescribed drug type diabetes nonetheless mechanism action biguanides remains imperfectly understood suggestion decade ago metformin reduces glucose synthesis activation enzyme amp-activated protein kinase ampk recently challenged genetic loss-of-function experiments provide novel mechanism metformin antagonizes action glucagon thus reducing fasting glucose levels mouse hepatocytes metformin leads accumulation amp related nucleotides inhibit adenylate cyclase reduce levels cyclic amp protein kinase pica activity abrogate phosphorylation critical protein targets pica block glucagon-dependent glucose output hepatocytes data support mechanism action metformin involving antagonism glucagon suggest approach development antidiabetic drugs 
